Rationale for a Phase I Trial of Erlotinib and the mTOR inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer
Rationale for a Phase I Trial of Erlotinib and the mTOR inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer. Clinical Cancer Research. 2007; (13):4628-4631.